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INTRODUCTION
Jra is a high-frequency antigen that has been included
in the 901 series (antigen number, 901005) of the Interna-
tional Society of Blood Transfusion blood group classifi-
cation [1]. The frequency of occurrence of this antigen is
known to be over 99% in most ethnic groups [2]. Although
the Japanese population is known to have the highest
number of Jr(a-) individuals, the incidence of the Jr(a-)
phenotype is estimated to be only 0.03-0.12% even in the
Japanese population [3], and this percentage is thought
to be lower in Caucasians, Mexicans, and Arabs [4]. The
incidence of the Jr(a-) phenotype in the Korean popula-
tion has not yet been reported.
Jra was first reported in 1970 by Stroup and MacIlroy
[5], who identified 5 cases in which anti-Jra antibody
was detected during the assessment of a high frequency
antigen in the Caucasian population. Although case
reports regarding anti-Jra antibody have been published
occasionally over the past 40 yr, its clinical significance
has not been well established. This is mainly because of
the diversity of patient outcomes and scarcity of report-
ed data. The 2 main clinical scenarios associated with
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anti-Jra positivity are incompatible transfusions and
hemolytic disease of the newborn and fetus (HDNF). In
the former scenario, no biologic or clinical evidence of
hemolysis due to mild, acute, or delayed transfusion reac-
tions has been reported for individuals with anti-Jra anti-
bodies [6]. In the latter scenario, limited availability of
data has led to conflicting results [6]. We present a case
of neonatal jaundice associated with anti-Jra alloimmu-
nization in premature twins; this case occurred during
the first pregnancy of a Korean woman. This is the first
report documenting HDNF related to anti-Jra alloimmu-
nization in Korea.
CASE REPORT
A 33-yr-old nulliparous woman in her 32nd gesta-
tional week visited the emergency room because of vagi-
nal bleeding. Her medical history was unremarkable
except for the fact that she was a hepatitis B carrier.
She had no history of blood transfusion or amniocente-
sis. She had a twin pregnancy after in vitro fertilization
and embryo transfer (IVF-ET). A routine obstetric exam-
ination revealed that vaginal bleeding was caused by pla-
centa previa, and the patient was admitted to undergo
conservative perinatal management.
Initial laboratory tests showed a low hemoglobin level
(10.9 g/dL). The antibody-screening test (Search-Cyte;
Medion Diagnostics AG, Du_dingen, Switzerland) yielded
weakly positive, irregular results in both the reagent
cells only in the antiglobulin phase. The patient’s ABO
and RhD blood type was O+. Antibody identification test
(Data-Cyte; Medion Diagnostics AG) revealed the pres-
ence of a pan-reactive antibody that showed weak posi-
tivity against all the 11 reagent panel cells in the antiglob-
ulin phase. The results of the antibody identification tests
conducted at room temperature and at 37℃ with albu-
min enhancement were negative. The indirect antiglob-
ulin test (IAT) with autologous control and direct antiglob-
ulin test (DAT) also yielded negative results. The anti-
body characteristics indicated that the corresponding
antigen was a high-frequency red blood cell (RBC) anti-
gen. Screening of the patient’s RBC phenotype with a
panel of antisera showed that the RBCs were positive for
k, Dib, and Lub. A negative reaction against Jra antiserum
prepared in-house confirmed the patient’s Jr(a-) phe-
notype. Crossmatching of the patient’s serum and previ-
ously confirmed Jr(a-) O+RBCs yielded negative results.
Because of frequent uterine contraction and vaginal
spotting, an emergency cesarean section was performed
at the 34th week of gestation. The patient delivered 2
premature male infants. Their body weight and Apgar
scores at 1 and 5 min after birth were as follows: baby 1,
1.91 kg, 4, and 7; baby 2, 2.2 kg, 5, and 8. Both babies
underwent phototherapy for the treatment of neonatal
jaundice. The results of the laboratory tests conducted
on the 4th day of birth are shown in Table 1. The ABO/
RhD blood type of baby 1 and baby 2 were O+ and A+,
respectively. The antibody screening and identification
test results of the 2 infants were similar to those of their
mother. In both tests, the serum of the 2 infants weakly
reacted with all the reagent-panel RBCs only in the
antiglobulin phase. IAT with autologous control yielded
positive results in both infants. The RBCs of both infants
showed reactivity with Jra antiserum; this confirmed the
Jr(a+) phenotype (the infants’RBCs were treated with
chloroquine to dissociate the antibodies on the RBC sur-
face before testing). Crossmatching with the infants’
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Abbreviations: WBC, white blood cell; LDH, lactate dehydrogenase.
Baby 1 Baby 2
Hemoglobin (g/dL) 14.6 13.8
Hematocrit (%) 43.6 41.3
WBC count (×103/mL) 14.78 10.74
Platelet count (×103/mL) 279 363
Bilirubin, total (mg/dL) 8.4 8.1
Bilirubin, direct (mg/dL) 1.1 0.9
LDH (IU/L) 522 394
ABO cell type O A
RhD Positive Positive
Direct Coombs’ (IgG) Positive (3+) Positive (1+)
Direct Coombs’ (IgA) Negative Negative
Direct Coombs’ (IgM) Negative Negative
Direct Coombs’ (C3d) Negative Negative
Direct Coombs’ (C3c) Negative Negative
Table 1. Results of laboratory tests conducted on the neonates
on the 4th day of birth
serum and previously confirmed Jr(a-) O+ RBCs showed
negative results. Antibody-identification test with the elu-
ate of the infants’RBCs was not performed because of
the inadequate quantity of the referred blood sample.
Taken together, these data indicated the presence of
anti-Jra antibodies of maternal origin in the twins’serum
and the role of these antibodies in the positive DAT results
in the neonates. The infants were discharged after con-
servative management on the 19th postpartum day, with-
out further complications.
DISCUSSION
Although the anti-Jra antibody was identified nearly
half a decade ago, its clinical significance with regard to
hemolytic reactions has not been clearly established. This
is mainly because of the paucity of reported data. In
most of the cases described in the literature, HDNF did
not occur, and when it did occur, its intensity was mild to
moderate, and hence, no treatment beyond phototherapy
was required [3, 4, 7-13]. A few cases of incompatible
Jr(a+) RBC transfusion with no or delayed hemolytic
transfusion reactions have also been reported [14-16].
However, recent evidence has shown that anti-Jra
antibodies have the potential for causing fatal HDNF
and acute hemolytic reactions. Acute hemolytic transfu-
sion reaction caused by anti-Jra antibodies has been
reported in a 45-yr-old Japanese woman [15]. Peyrard
et al. [6] reported the first case of fatal HDNF in a 28-
yr-old Caucasian woman of Spanish Gypsy origin. She
had an obstetric history of 2 abortions and 1 full-term
pregnancy (G4P1). At the time of the first abortion, she
developed massive hemorrhage that required transfusion
of 10 units of RBCs. Fetal cardiomegaly associated with
intrauterine growth retardation was confirmed at the
35th week of her 4th pregnancy. An emergency cesare-
an section was performed at the 36th week. The newborn
was hydropic, had severe anemia, and died 30 hr after
birth. Anti-Jra antibodies, which were later identified in
the mother’s serum, were thought to be the cause of severe
fetal anemia. Arriaga et al. [17] also reported a similar
fatal case of hydrops fetalis associated with anti-Jra anti-
bodies in a 39-yr-old Caucasian woman with a history
of multiple pregnancies. An earlier case reported in 2006
also described severe fetal anemia in a 40-yr-old Japanese
woman (G4P3), but the infant was born healthy after 4
intravascular transfusions via the umbilical cord [18].
The common feature of the 3 cases of HDNF described
above is that the mothers had multiple pregnancies with
or without transfusion history. In many previously pub-
lished cases reporting no or mild to moderate clinical
HDNF associated with anti-Jra antibody positivity, the
Jr(a-) pregnant women had no transfusion history [6].
Thus, it can be presumed that the clinical significance of
the anti-Jra antibody may depend on the frequency of
exposure to the Jra antigen. Previous studies have shown
that anti-Jra antibodies may develop during pregnancy
and that they can cross the placenta [3, 9]. The Jra anti-
gen has also been reported to be fully developed at birth
[7]. Although anti-Jra antibodies can be stimulated by a
first pregnancy, HDNF associated with anti-Jra antibody
was thought to occur in subsequent pregnancies [6]. How-
ever, in our case, the mother was nulliparous and had
no history of transfusion or amniocentesis. The present
pregnancy was the only identifiable cause of alloimmu-
nization. Although confirmative findings such as nega-
tive antibody screening test results before the present
pregnancy were not available, it should be noted that
the findings in this case suggest that HDNF can occur in
a first pregnancy. This may probably be the reason for
the low severity of HDNF. Another interesting finding
was that the DAT results for both neonates were posi-
tive and that the positivity in the DAT result of baby 1,
whose ABO/Rh blood type was O+, was greater than
that in the DAT result of baby 2. The reasons for the
differences in DAT results are not clear. The effect of
having twins on anti-Jra alloimmunization requires fur-
ther investigation. Although we could not evaluate the
eluates of the twin’s RBCs because of lack of specimens,
the presence of anti-Jra antibodies in the twin’s serum
and the Jr(a+) phenotype of the twin’s RBCs indicated
that anti-Jra antibodies were the cause of the positive
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DAT results.
Several in vivo and in vitro studies have been performed
to assess the clinical significance of anti-Jra antibodies.
Kendall [14] performed the traditional 51Cr RBC survival
test and showed the moderately rapid destruction of
incompatible Jr(a+) RBCs after transfusion to a Jr(a-)
patient. Ogasawara and Mazuda [19] reported that the
Jra antigen density was lower than the D-antigen den-
sity in RBCs with a weak D phenotype and was signifi-
cantly lower than the density of high-incidence antigens
such as Dib. They concluded that the small number of
antigens on the RBC membrane may account for the
general lack of clinical significance of anti-Jra antibod-
ies. Miyazaki et al. [20] described that the fluorescence
intensity of Jr(a+) RBCs was significantly lower than
that of E+ RBCs from E homozygotes; this finding sug-
gested that the number of Jra antigen sites is substan-
tially lower than that of Rh antigen sites. The monocyte
monolayer assay (MMA) has also been used in some stud-
ies to predict the potential clinical significance of anti-
bodies to high-frequency antigens [15, 21, 22]. However,
the exact mechanism of the toxicity of anti-Jra antibod-
ies remains unclear.
One of the difficulties in identifying anti-Jra antibod-
ies is the lack of commercially available antisera. A human
monoclonal anti-Jra antibody has been produced from a
human-mouse heterohybridoma (HMR0921) [20]. How-
ever, the biochemical structure of the Jra antigen and the
molecular basis of the Jr(a-) phenotype are currently
unknown [6]. Our laboratory has been identifying anti-
Jra antibodies since 1995 after donation of Jra antisera
and Jr(a-) type O RBCs obtained from Osaka Red Cross
Center. We are currently using in-house Jra antisera
and Jr(a-) RBCs prepared by constantly storing con-
firmed patient samples. Although we have been identi-
fying a few cases of anti-Jra alloantibodies annually, this
is the first case of HDNF related to anti-Jra alloimmu-
nization in Korea. The first case of anti-Jra alloimmu-
nization in Korea was reported in 1995 in a 35-yr-old
pregnant woman with a history of multiple pregnancies
and abortions (G6P4L1D3A1) [23]. Anti-Jra antibodies were
identified after an anamnestic response following the
transfusion of 1 RBC unit. However, the infant did not
show any evidence of HDNF. Because a large percentage
of Jr(a-) individuals appear to be of Asian origin [18],
further studies on the incidence of the Jr(a-) phenotype
in the Korean population may reveal interesting findings.
In conclusion, the potential of the anti-Jra antibody as
a clinically significant alloantibody should be considered
even in cases of first pregnancy. Preventive management
and close fetal monitoring are recommended, especially
if the mother has a high antibody titer and a history of
multiple pregnancies and/or transfusion. Because Jr(a-)
RBC units are very difficult to obtain, measures must be
taken to ensure the availability of appropriate blood types.
Autologous donations should always be considered; sib-
lings are also potential donors of Jr(a-) RBCs. In emer-
gent situations where Jr(a-) RBCs are not available,
transfusion of the least incompatible units is inevitable.
Nevertheless, close monitoring of the patient is neces-
sary while performing subsequent transfusions.
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